Mongolian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Familial Hypercholesterolemia in Turkey (A-HIT2)

Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
Холбоосыг санах ойд хадгалдаг
СтатусДууссан
Ивээн тэтгэгчид
Ege University
Хамтран ажиллагсад
Turkish Society of Cardiology

Түлхүүр үгс

Хураангуй

A-HIT2, is also designed as a National FH registry. At least 1000 FH patients will be recruited from 30 outpatient clinics representing the 12 Nuts statistical Regions in Turkey proportional to the 2015 Turkey's Population distribution.[14] Both HeFH and HoFH patients are eligible for enrollment. Sites specialized on cardiology, internal medicine, and endocrinology were invited by the Turkish Society of Cardiology.

Тодорхойлолт

At least 1000 FH patients will be recruited from 30 outpatient clinics representing the 12 Nuts statistical Regions in Turkey proportional to the 2015 Turkey's Population distribution. Both HeFH and HoFH patients are eligible for enrollment. Sites specialized on cardiology, internal medicine, and endocrinology were invited by the Turkish Society of Cardiology. The primary objective of this cross-sectional study, is to detect the clinical status and management of the patients diagnosed with FH in Turkey. The secondary objectives are; to detect the pattern of clinical presentation, to know the medication use, to define the clinical response to LLT, to evaluate the attainment of LDL-cholesterol goals and to identify resistance and/or intolerance to LLT. Defining the CV risk factors and approach to these factors by the physicians, and comparing the attitudes in different specialty groups (cardiology, endocrinology and internal medicine) are also among the secondary objectives of the registry. Eligibility for screening was defined as having LDL-cholesterol levels > 160 mg/dl either as on treatment or untreated values. Centers may enroll both incident and prevalent patients. The inclusion criteria included age > 18 years and being diagnosed as possible FH. The possible FH was defined as having a total score of > 2 according to Dutch lipid clinic network (DLCN) criteria. Patients with triglyceride levels > 400 mg/dl or secondary hyperlipidemia (ie, untreated hypothyroidism, nephrotic syndrome, cholestasis, etc..) will be excluded from the study. Two different data sets will be collected for A-HIT2. The physicians will complete electronic case report forms for each patient Patients will also complete a short survey to assess the level of disease awareness. This survey is also designed to give information on the patients' perceptions and knowledge on cholesterol, its harm, and LLT. All data will be collected in a single visit. Data verification will be based on the source document control of 5% sample randomly selected per center.

Огноо

Сүүлд баталгаажуулсан: 11/30/2017
Эхлээд оруулсан: 04/02/2017
Тооцоолсон элсэлтийг оруулсан: 04/05/2017
Эхлээд нийтэлсэн: 04/11/2017
Сүүлийн шинэчлэлтийг оруулсан: 12/04/2017
Сүүлийн шинэчлэлтийг нийтэлсэн: 12/06/2017
Сургалтын бодит эхлэх огноо: 02/25/2017
Тооцоолсон анхан шатны ажил дуусах огноо: 11/29/2017
Судалгааны ажлыг дуусгах өдөр: 12/04/2017

Нөхцөл байдал эсвэл өвчин

Familial Hypercholesterolemia
Atherosclerosis

Үе шат

-

Эрхийн шалгуур

Суралцах боломжтой нас 18 Years Хэнд 18 Years
Суралцах боломжтой хүйсAll
Дээж авах аргаNon-Probability Sample
Эрүүл сайн дурын ажилтнуудыг хүлээн авдагТийм ээ
Шалгуур үзүүлэлтүүд

Inclusion Criteria:

- age > 18 years and being diagnosed as possible FH.

- The possible FH was defined as having a total score of > 2 according to Dutch lipid clinic network (DLCN) criteria

Exclusion Criteria:

- Patients with triglyceride levels > 400 mg/dl or secondary hyperlipidemia (ie, untreated hypothyroidism, nephrotic syndrome, cholestasis, etc..) will be excluded from the study.

Үр дүн

Анхан шатны үр дүнгийн арга хэмжээ

1. number of patients receiving proper treatment for FH [February- November 2017]

how many patients are receieving the proper lipid lowering drugs for the diagnosis of FH

Хоёрдогч үр дүнгийн арга хэмжээ

1. number of patients reaching LDL-cholesterol goal according to risk status (risk level) [February- November 2017]

how patients diagnosed with FH in Turkey are managed, that is to what percent they reach ldl goals.

Манай facebook
хуудсанд нэгдээрэй

Шинжлэх ухаанаар баталгаажсан эмийн өвс ургамлын бүрэн мэдээллийн сан

  • 55 хэл дээр ажилладаг
  • Шинжлэх ухааны үндэслэсэн ургамлын гаралтай эдгэрэлт
  • Ургамлыг дүрсээр таних
  • Интерактив GPS газрын зураг - эмийн ургамлыг байршлаар нь тэмдэглэнэ (удахгүй)
  • Хайлттай холбоотой шинжлэх ухааны нийтлэлүүдийг уншина уу
  • Эмийн өвсийг үр нөлөөгөөр нь хайж олох
  • Мэдээллийн судалгаа, клиник туршилт, патентыг цаг тухайд нь сонирхож, зохион байгуул

Шинж тэмдэг эсвэл өвчний талаар бичиж, тус болох ургамлын талаар уншиж, өвслөг ургамлыг бичиж, өвчний эсрэг шинж тэмдгийг үзээрэй.
* Бүх мэдээлэл нь хэвлэгдсэн эрдэм шинжилгээний судалгаанд үндэслэсэн болно

Google Play badgeApp Store badge